Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A | P37088 | 5/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 9/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.42 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2017964 | 0.94 | SCNN1A (0.44) | SCNN1AS1PR1HTTACSS2TP53 | |
| SCHEMBL2016536 | 0.92 | HTT (0.42) | SCNN1AHTTMTNR1AMTNR1BACSS2 | |
| SCHEMBL12635952 | 0.91 | HTT (0.41) | SCNN1AS1PR1HTTMTNR1AMTNR1B | |
| SCHEMBL12635701 | 0.90 | ACSS2 (0.49) | SCNN1AS1PR1HTTMTNR1AMTNR1B | |
| SCHEMBL2018430 | 0.90 | ACSS2 (0.42) | SCNN1AHTTACSS2 | |
| SCHEMBL2017976 | 0.89 | HTT (0.40) | SCNN1AS1PR1HTTACSS2TP53 | |
| SCHEMBL2022069 | 0.89 | ACSS2 (0.47) | SCNN1AHTTACSS2 | |
| SCHEMBL2040435 | 0.88 | HTT (0.45) | HTTACSS2TP53MAPTSMN1; SMN2 | |
| SCHEMBL2020165 | 0.88 | ACSS2 (0.46) | SCNN1AHTTACSS2 | |
| SCHEMBL2016331 | 0.87 | HTT (0.52) | SCNN1AHTTACSS2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3245200-B1 | 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL)BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-10 | — | — | EP | disclosed |
| US-9981954-B2 | 2-(pyrazin-2-ylcarbonylaminomethyl) benzimidazolium compounds as epithelial sodium channel inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-05-29 | — | — | US | disclosed |
| US-9981954-B2 | 2-(pyrazin-2-ylcarbonylaminomethyl) benzimidazolium compounds as epithelial sodium channel inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-05-29 | — | — | US | disclosed |
| US-20180002314-A1 | 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL) BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-01-04 | — | — | US | disclosed |
| WO-2016113168-A1 | 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL)BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-07-21 | — | — | WO | disclosed |
| WO-2011079087-A1 | ENAC BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079087-A1 | ENAC BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002314-A1 | 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL) BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS | SCNN1A, TRPV1, SCNN1B | SCNN1A 1/4885S1PR1 1253/4885HTT 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.